Advanced search
1 file | 341.69 KB

Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN) : a multicentre, randomised, phase 3 trial

(2018) LANCET ONCOLOGY. 19(12). p.1617-1629
Author
Organization
Keywords
COLONY-STIMULATING FACTOR, STAGE 4 NEUROBLASTOMA, INDUCTION, CHEMOTHERAPY, 13-CIS-RETINOIC ACID, CHO-CELLS, CANCER, THERAPY, CYTOTOXICITY, COMBINATION, MELPHALAN

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 341.69 KB

Citation

Please use this url to cite or link to this publication:

Chicago
Ladenstein, Ruth, Ulrike Poetschger, Dominique Valteau-Couanet, Roberto Luksch, Victoria Castel, Isaac Yaniv, Genevieve Laureys, et al. 2018. “Interleukin 2 with anti-GD2 Antibody ch14.18/CHO (dinutuximab Beta) in Patients with High-risk Neuroblastoma (HR-NBL1/SIOPEN) : a Multicentre, Randomised, Phase 3 Trial.” Lancet Oncology 19 (12): 1617–1629.
APA
Ladenstein, R., Poetschger, U., Valteau-Couanet, D., Luksch, R., Castel, V., Yaniv, I., Laureys, G., et al. (2018). Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN) : a multicentre, randomised, phase 3 trial. LANCET ONCOLOGY, 19(12), 1617–1629.
Vancouver
1.
Ladenstein R, Poetschger U, Valteau-Couanet D, Luksch R, Castel V, Yaniv I, et al. Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN) : a multicentre, randomised, phase 3 trial. LANCET ONCOLOGY. 2018;19(12):1617–29.
MLA
Ladenstein, Ruth et al. “Interleukin 2 with anti-GD2 Antibody ch14.18/CHO (dinutuximab Beta) in Patients with High-risk Neuroblastoma (HR-NBL1/SIOPEN) : a Multicentre, Randomised, Phase 3 Trial.” LANCET ONCOLOGY 19.12 (2018): 1617–1629. Print.
@article{8587388,
  author       = {Ladenstein, Ruth and Poetschger, Ulrike and Valteau-Couanet, Dominique and Luksch, Roberto and Castel, Victoria and Yaniv, Isaac and Laureys, Genevieve and Brock, Penelope and Michon, Jean Marie and Owens, Cormac and Trahair, Toby and Chan, Godfrey Chi Fung and Ruud, Ellen and Schroeder, Henrik and Popovic, Maja Beck and Schreier, Guenter and Loibner, Hans and Ambros, Peter and Holmes, Keith and Castellani, Maria Rita and Gaze, Mark N and Garaventa, Alberto and Pearson, Andrew DJ and Lode, Holger N},
  issn         = {1474-5488},
  journal      = {LANCET ONCOLOGY},
  language     = {eng},
  number       = {12},
  pages        = {1617--1629},
  title        = {Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN) : a multicentre, randomised, phase 3 trial},
  url          = {http://dx.doi.org/10.1016/S1470-2045(18)30578-3},
  volume       = {19},
  year         = {2018},
}

Altmetric
View in Altmetric
Web of Science
Times cited: